<DOC>
	<DOC>NCT01801280</DOC>
	<brief_summary>The objective of this pharmacokinetic study is to examine a possible drug-drug interaction of Pantoprazole on the bioavailability mycophenolic acid administered as either Mycophenolate mofetil (Cellcept(R) or Mycophenolate Sodium; EC-MPS (Myfortic (R) in stable renal allograft recipients under maintenance immunosuppressive therapy (cyclosporine +/- low dose glucocorticoids).</brief_summary>
	<brief_title>Influence of Pantoprazole on the Bioavailability of MMF and EC-MPS</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<criteria>patients &gt;18 years old patients who are under stable immunosuppressive therapy for at least one month with ciclosporin, ECMPS or MMF +/ corticosteroids renal transplantation, at least 6 months prior study inclusion suitable and willing to switch treatment according to the study plan women of childbearing potential must have a negative serum pregnancy test before study start and effective contraception must be used (method with PEARL index &lt; 1%) patients with renal function &lt; 30ml/min (estimated by Cockcroft Gault formula) patients who are not on stable treatment with enzyme inductors or enzymes inhibitors for &lt;1month before study entry patients who take medication which is known for interfering with MPA absorption for &lt;1month before study entry known anamnestic hypersensitivity to one of the investigational products or drugs with similar chemical structure and to other components of the investigational products, respectively patients on treatment with clopidogrel acute rejection &lt; 1 month before study inclusion patients who are HIV positive, hepatitis C virus (HCV) positive, HBsAg positive patients with gastrointestinal disorders which could affect resorption pregnancy and/or lactation drug or alcohol abuse in patient's history patients with history of psychological illness or condition, which might interfere with the ability to understand the requirements, consequences, possible outcome of the study and patients who are not willing to give valid informed consent patients with insufficient cooperation with the clinical investigator (e.g. suspicion of noncompliance)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>immunosuppressive medication</keyword>
	<keyword>mycophenolic acid</keyword>
	<keyword>interaction</keyword>
	<keyword>proton pump inhibitor</keyword>
	<keyword>pantoprazole</keyword>
	<keyword>renal transplant patients</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>bioavailability</keyword>
</DOC>